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Gaining knowledge of the neoplastic side of the three main cells—B cells, Follicular Helper
T (Tfh) cells, and follicular dendritic cells (FDCs) —involved in the germinal center (GC)
reaction can shed light toward further understanding the microuniverse that is the GC,
opening the possibility of better treatments. This paper gives a review of the more complex
underlying mechanisms involved in the malignant transformations that take place in the
GC. Whilst our understanding of the biology of the GC-related B cell lymphomas has
increased—this is not reviewed in detail here—the dark side involving neoplasms of Tfh
cells and FDCs are poorly studied, in great part, due to their low incidence. The aggressive
behavior of Tfh lymphomas and the metastatic potential of FDCs sarcomas make them
clinically relevant, merit further attention and are the main focus of this review. Tfh cells and
FDCsmalignancies can often be misdiagnosed. The better understanding of these entities
linked to their molecular and genetic characterization will lead to prediction of high-risk
patients, better diagnosis, prognosis, and treatments based on molecular profiles.
Keywords: peripheral T-cell lymphomas, angioimmunoblastic T cell lymphoma, follicular T-cell lymphoma, follicular
dendritic cell sarcomas, follicular lymphoma, Burkitt lymphoma, diffuse large B cell lymphomaINTRODUCTION
The germinal center (GC), a specialized microstructure with a high rate of cell division, is the site
where antigen-driven somatic hypermutation (SHM) occurs (1, 2), a process that ultimately will
produce high-affinity antibodies during adaptive immune responses (3). Over weeks, memory B
cells and high-affinity antibody producing plasma cells will generate from GCs, which are necessary
to protect against invading microorganisms (4). However, the more potent the immune response,
the greater the risk of autoreactivity or malignancy. This is particularly relevant for the GC, where B
cells may have an unfavorable outcome driving to lymphomagenesis. Importantly, most of B−cell
lymphomas originate from GC B cells (5–7).January 2021 | Volume 10 | Article 5878091
Munguı́a-Fuentes et al. Tfhs and FDCs MalignanciesTo succeed during GC reactions, B cells need the help of other
crucial cells, such as Follicular Helper T (Tfh) cells and follicular
dendritic cells (FDCs). Here, we focus on one dark side of GCs:
malignancies derived from their aforementioned three players,
B-cells, Tfh cells, and FDCs (Figure 1), with greater emphasis on
Tfh lymphomas and FDC sarcomas (Table 1).THE GERMINAL CENTER
GCs arise from proliferating B cells in the follicles of peripheral
lymphoid tissues during T cell-dependent antibody responses.
Naïve B cells encountering their antigen migrate to the T-B
border, where they become fully activated during interaction
with cognate CD4+ T cells (3, 4, 8–12). The engagement of CD40
by CD40L (CD154) represents the major component of the T cell
help. Activated B cells can then either differentiate rapidly into
antibody-secreting plasma cells in specialized extra-follicular
niches or mature their affinity for the antigen into GC
reactions, a microstructure of B cells, in a high-rate of cell
division, Tfh cells and a network of FDCs (3, 13, 14). There, B
cells begin to proliferate rapidly giving rise to the distinctive
structure of the GC: a dark zone (DZ) of centroblast proliferating
B cells and a light zone (LZ) with higher frequencies of smaller,Frontiers in Oncology | www.frontiersin.org 2non-dividing centrocytes. GC DZ B cells undergo SHM, and
those cells that improved the affinity for the antigen are selected
in the LZ to eventually differentiate into memory B cells or
plasma cells (3, 4, 15, 16).THE DARK SIDE OF GC B CELLS
The GC response, beneficial for the host during immune
responses against invading pathogens, may have a detrimental
role, the development of malignancies. B cells inside GC
reactions are mutating at much higher rates than in any other
site in the body (17), these mutations might turn B cells into a
dark side, B cell lymphomas. Except the relatively rare
lymphoblastic and mantle-cell lymphoma subtypes, B cell non-
Hodgkin lymphomas (B−NHLs)—including diffuse large B cell
lymphoma (DLBCL), follicular lymphoma (FL) and Burkitt
lymphoma (BL)—are derived from GC B cells. This can be
demonstrated by the presence of SHM in the immunoglobulin
genes, together with histological, immunophenotypic, and gene
expression characteristics (5, 18–23).
Our understanding of the molecular mechanisms driving GC
lymphomas has increased due to next-generation sequencing
(24). Gene translocations targeting MYC, BCL2 and BCL6, asFIGURE 1 | Germinal Center-derived malignancies’ players. The GC (1) is the site for B cell affinity maturation for the antigen through somatic hypermutation (in the
DZ) and for antigen-driven selection of B cells which have improved their affinity (in the LZ). To success the reaction, the help from Tfh cells is fundamental, as well
as, the presence of the antigen on iccosomes on FDCs. Eventually, GC B cells will differentiate to PCs or MBCs. However, the GC response may have a detrimental
role, the development of malignancies from their three main players: B-cells, Tfh cells and FDCs. Follicular lymphoma cells (2) derive from follicles partly resembling
normal GCs and depend on Tfh cells and FDCs to survive, while Tfh cells provide a high production of IL-4 and CD40L, FDCs provide a scaffold attracting FL cells
and Tfh cells around them. (3) Infiltration of different immune cells and the proliferation of FDCs and HEV in AITL are probably caused by a stimulatory niche,
secreting IL-21, IL-4 or/and IL-6, CXLC13 and VEGF, promoting a loop of Tfh cell generation and FDCs growth. (4) Tfh and Treg cells seem to be enriched in FDC
sarcomas with high levels of PD-1 and its ligands PD-L1 and PD-L2 and the B/T cells mixed with the neoplastic population, altogether supporting the neoplastic
niche and the evasion of effector immune cells. See text for further details.January 2021 | Volume 10 | Article 587809
Munguı́a-Fuentes et al. Tfhs and FDCs Malignancieswell as the disruption of the epigenome, predominantly driven by
somatic mutations within KMT2D, CREBBP, EZH2, and linker
histones, have been well-established (25–29). The molecular and
genetic characterization of these diseases will lead to prediction
of high-risk patients and treatments based on molecular
profiles (24).Frontiers in Oncology | www.frontiersin.org 3DIFFUSE LARGE B CELL LYMPHOMA
DLBCL and FL are the two most common forms of GC NHLs.
With a greater degree of genetic heterogeneity than FL, DLBCL
can be divided into at least two major subtypes: GC B cell (GCB)-
like and activated B cell (ABC)-like DLBCL (24, 25, 30). WholeTABLE 1 | Lymphomas of Follicular Helper T (Tfh) cells and sarcomas of follicular dendritic cells (FDCs).
Incidence
and OS
Clinical features Morphology Immunophenotype Genetic profile Treatment
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and the characterization of new genetic DLBCL subtypes. A
recent study identified five genomic clusters based on the
enriched genetic feature of each group (31). MYD88 cluster
[with MYD88 (L265P), PIM1, CD79B and ETV6 mutations]
were strongly associated with ABC subtype. Three clusters were
associated to GCB subtype (BCL2, SOCS1/SGK1, and TET2/
SGK1). The BCL2 cluster showed mutations of EZH2, BCL2,
CREBBP, TNFRSF14, KMT2D, and MEF2B. The SOCS1/SGK1
cluster with mutations in SOCS1, CD83, SGK1, NFKBIA,
HIST1H1E, and STAT3; and the TET2/SGK1 cluster
characterized by mutations including TET2, SGK1, KLHL6,
ZFP36L1, BRAF, MAP2K1, and KRAS. A NOTCH2 cluster
with mutations on NOTCH2, BCL10, TNFAIP3, CCND3,
SPEN, TMEM30A FAS, and CD70 showed a mixture of ABC,
GCB and unclassified DLBCL. This study correlated with two
recent studies classifying the disease (32, 33). Importantly,
patient outcome was evaluated with the worst prognosis in the
MYD88 group (42% 5-year overall survival, OS). Patients within
the GCB-associated clusters had better 5-year OS (> 60%) while
NOTCH2 cluster had intermediate survival (53.6% 5-year OS).
Patient outcome correlated with previous studies (24, 34–38).FOLLICULAR LYMPHOMA
FL is the most frequent indolent and incurable NHL. Over time FL
may progress to DLBCL, with a more aggressive clinical course
requiring more aggressive treatment (39, 40). Malignant cells
morphologically resemble the two B cell subsets found in reactive
GCs (centrocytes and centroblasts). Low-grade FL cases (grade 1–2)
contain <15 centroblasts per high-power microscopic field (40 x
objective, 0.159 mm2) while grade 3 contains >15 centroblasts,
evaluated in 10 different follicles. Grade 3 FL is further separated in
3A with a background of centrocytes present or grade 3B with
follicles composed entirely of centroblasts. A diffuse pattern of 3B
grade cells is compatible with DLBCL diagnosis (41, 42). The
molecular pathogenesis of FL includes the high recurrence of two
mutations: chromosomal translocations that lead to the ectopic
expression of BCL2 and somatic mutations in the histone
methyltransferase MLL2 (also known as KMT2D) (43). Also,
histone modifiers such as EZH2, CREBBP and EP300 are
frequently altered in FL (44–46). While BCL2 translocation is
thought to occur in B-cell precursors in the bone marrow, the
translocation is found also in healthy humans (40%) (47). This
supports the hypothesis that the translocation is necessary, but not
sufficient for FL and probably lymphomagenesis is consequence of
antigen stimulation (48, 49).
FL derives from follicles partly resembling normal GCs, with
the FL cells depending on Tfh cells and FDCs. While Tfh cells
provide a high production of IL-4 and CD40L as survival factors
of FL cells, FDCs provide a scaffold attracting FL cells and Tfh
cells around them. FDCs also contributes with a positive
feedback through the overexpression of stromal cell-derived
factors, supporting the abnormal production of IL-4 (50, 51).Frontiers in Oncology | www.frontiersin.org 4BURKITT LYMPHOMA
BL is a highly aggressive NHL associated with Epstein-Barr virus
(EBV), human immunodeficiency virus (HIV) or Plasmodium
infection. Three clinical variants of BL are recognized: endemic
BL, sporadic BL and immunodeficiency-associated BL. Whilst
EBV and Plasmodium are associated to endemic and sporadic
BL, HIV is associated to the immunodeficiency-related variant
(52, 53). BL derives from DZ GC B cells, as indicated by its
genetic profile (20, 23, 54). Although the potential pathological
role of EBV in BL it is still controversial, the virus is present in all
BL cases. Aberrant expression of MYC and the BCR-induced
PI3K signalling pathway activation are genetic alterations that
are common in BL (23, 55, 56).FOLLICULAR HELPER T CELLS
Fundamental studies by Mitchison in the 1970’s established the
essential role of T helper cells in antibody responses. Hapten-
protein carrier conjugates revealed that carrier-specific T cells
were necessary for the maturation of hapten-specific B cells [(57)
and reviewed in Ref (10)]. Then, it was described that this help
from T cells consisted in co-stimulatory signals through CD40
ligand (CD40L) to B cells leading them to proliferate,
differentiate, and antibody class-switching (10, 58). T cells in
the T-B border that have undergone T-B interactions can
migrate inside the follicles as Tfh cells, afterwards making
cognate interactions with GC B cells within the GC reaction. T
cell help into GCs are needed to maintain the reaction (59–63).
At present, a combination of markers is needed to identify
Tfh cells as a distinct population. Tfh cells differentiate from the
classical CD4+ T cell subpopulation and share plastic
characteristics with other CD4+ helper T cells until they
engaged in GC reactions. Inside GCs, the expression of
typically described Tfh cells associated-molecules—CXCR5,
PD-1, BCL6, BTLA4, ICOS (inducible T cell costimulator) and
SAP—is upregulated whilst CD127, PSGL1, and EBI2 are
downregulated (64–66). When these molecules are low-
intermediate expressed, particularly CXCR5, PD-1, ICOS and
SAP, define stage known as pre-GC Tfh cells (10, 66–69).FOLLICULAR HELPER T CELLS IN
MALIGNANCY
Peripheral T-cell lymphomas (PTCLs) are generally described as
diverse and aggressive malignancies with unfavorable therapeutic
outcomes (70). Nodal T-cell lymphomas with Tfh-cell phenotype
are classified into three diseases: angioimmunoblastic T cell
lymphoma (AITL), follicular T-cell lymphoma (FTCL) and nodal
PTCL with Tfh cell phenotype. AITL is an aggressive rare tumor
with a 5-year survival of only 33%, first described as a distinct clinic-
pathologic entity in the 1970s and is the best well-established
subtype of mature PTCL (71, 72). The tumors contain neoplasticJanuary 2021 | Volume 10 | Article 587809
Munguı́a-Fuentes et al. Tfhs and FDCs MalignanciesTfh cells expressing BCL-6, CD10, CXCL13, PD-1, ICOS, SAP, and
CXCR5 (10, 73–75). TET2, DNMT3A and IDH2 mutations have
been detected in about 80% (76–78), 20–30% (76, 79, 80), and 20–
30% of the cases (81), respectively. The mechanism of action
described for these molecules is by dysregulating DNA
methylation (70). A missense mutation in RHOA GTPase is
detected in 50–70% AITL patients (77, 78, 82, 83). It has been
described that some primary cutaneous T cell lymphomas also
originate from neoplastic cells that express Tfh cells markers, and
can also induce the typical rosettes found in AITL (84).
Representative clinical symptoms of AITL are generalized
lymphadenopathy, hepatosplenomegaly, fever, effusion/ascites
and skin rash. The incidence is low without sex predilection,
affecting advanced-age individuals (median age of diagnosis 65
years) (72). Characteristically, lymph nodes acquire an effaced
architecture, with only a few benign follicles been retained. A
typical feature is to find infiltration beyond the capsule of the
lymph node, with a preserved but enlarged subcapsular sinus;
also high endothelial venules (HEV) and FDCs proliferate (71).
Infiltration of other cells include: B cells, plasma cells,
eosinophils, histiocytes and epithelioid cells. Active EBV
infection can be found in most large B cells, whilst the
malignant Tfh cells do not (72).
Cytological diagnosis of AITL is usually difficult and both
reactive and lymphomatous processes need to be discarded.
Combination of conventional cytology, immunocytochemistry
and flow cytometry is needed to make an accurate diagnosis (85).
AITL, a lymphoma with poor prognosis, is often refractory to
chemotherapy or relapses. Due to the unfavorable outcomes for
PTCL patients treated with chemotherapy alone, autologous
stem cell transplantation (SCT), as a consolidation treatment
for first-line therapy or salvage therapy for relapse/refractory
PTCL patients, may be an option. On the other hand, some
relapse/refractory AITL patients may benefit from allogenic-
SCT, presumably because of graft-versus lymphoma effects (74).
FTCL presents clinical and immunophenotype features of
AITL but differs histologically. Two patterns have been
described, one shows a GC-like growth with IgD+ B cells
surrounding the neoplastic cells and the second resembles a
FL-like pattern with malignant cells forming nodules. Another
difference with AITL is the absence of proliferation of HEVs and
FDCs (86).
While TET2, RHOA and DNMT3A mutations have been
shown in both, AITL and FTCL, there is no evidence of IDH2
mutation in FTCL (87). Also, 20% of cases show a t(5;9) (q33;
q22) (ITK/SYK) translocation but studies are limited (88).
The study and characterization of normal Tfh cells
phenotyping led to the recognition and classification of
previously diagnosed PTCLs-NOS (Not otherwise specified) to
Nodal PTCLs with Tfh cell phenotype (84). While clinical,
phenotypic, pathological, and genetic features overlap with
AITL, further research is needed to include this neoplasm
within the spectrum of one entity. Differences with AITL
include the absence of expansion of HEVs and FDCs while
histological differences from FTCL are due to the diffuse pattern
of Nodal PTCLs with Tfh cell phenotype (86, 89).Frontiers in Oncology | www.frontiersin.org 5TFH LYMPHOMAS AND THE
INTERACTION WITH THEIR NICHES
The interaction of neoplastic Tfh cells and their niches has not
been extensively studied. The reported infiltration of different
immune cells and the proliferation of FDCs and HEV in AITL
are probably caused by a stimulatory niche but the underlying
mechanisms are still unknown. Some signals present in a normal
counterpart niche like IL-21, IL-4, or/and IL-6 are over-
expressed in AITL creating a loop of Tfh cell generation and
FDCs growth (84, 90, 91). Also, this microenvironment could
explain in part the depletion of Treg cells in AITL, an important
population for suppressing Tfh cells in immune responses (92).
Regulatory CAR T cells therapy might be a potential treatment to
re-establish a favorable microenvironment.
Although neoplastic cells in FTCL show a GC- or follicle-
growth pattern, the low incidence of this malignancy has made
difficult the in-depth study of their interaction with resident cells.
Understanding the crosstalk between neoplastic cells and their
niche would definitely potentiate the development of more
rationale treatments.FOLLICULAR DENDRITIC CELLS:
ORIGIN AND FUNCTION
Originally discovered by Alexander Maximow and subsequently
termed FDCs by Steinman et al. in 1978, FDCs are critical
participants in the GC reaction (93–96).
FDCs are stromal cells residing exclusively in B cell follicles,
where they play a key role supporting B cell homeostasis and
maintaining the follicular architecture. They are essential
promoting robust humoral immune responses through the
retention of antigens within immune complexes (ICs) over
long periods. For this, FDCs express complement receptors
(CRs)-1 and -2 and can be induced to express Fc-gamma
receptor (FcyR) IIb (93, 97). Lymphoid organs lacking B cells
or tumor necrosis factor (TNF) or lymphotoxin (LT) are devoid
of FDCs (98–100). Mice lacking stromal CR1 and CR2 have
reduced T-dependent antibody responses (93, 98, 101). ICs are
released in FDCs-derived iccosomes, then cognate GC B cells can
acquire antigen and present it to Tfh cells. FDCs also support the
proliferation of GC B cells enhancing antibody production
(93, 98).
FDCs are a subset very different from conventional DCs (cDCs).
FDCs originate from stromal cells: it has been shown that in the
spleen, FDCs come from vascular mural cells but in the lymph
nodes, FDCs come frommarginal reticular cells (MRCs) (102, 103).
Nowadays, it is suggested that different stromal cells of secondary
lymphoid organs—including FDCs andMRCs—are generated from
one and the same precursor (93).
Functionally, whereas cDCs activate naïve T cells by presentation
of processed antigens via major histocompatibility complex
(MHC) molecules, FDCs show unprocessed antigens, trapped
in ICs, to GC B cells. In addition, FDCs secrete the signalling
molecule Mfge8 which has been shown to be essential inJanuary 2021 | Volume 10 | Article 587809
Munguı́a-Fuentes et al. Tfhs and FDCs Malignanciescontrolling the removal of apoptotic GC B cells. It has been
suggested that FDC-mediated phagocytosis of apoptotic GC B
cells might play an important role in avoiding autoimmunity (93).FOLLICULAR DENDRITIC CELLS
TURNING TO THE DARK SIDE:
FDC SARCOMA
Termed FDC sarcomas, the first reported cases of tumors derived
from FDCs occurred in cervical lymph nodes. FDC sarcoma is
classified as a distinct entity by the World Health Organization
(WHO) under histiocytic and DC neoplasms Classification of
Tumours. It is described as a neoplastic proliferation of spindled
to ovoid cells with morphologic and immunophenotypic
characteristics similar to those of normal FDCs. Despite the fact
that their histopathological, morphological and clinical features
have been described relatively in detail, their clinical course is
unpredictable and no specific treatment is available (95, 104).
While FDC sarcomas do not have gender predilection, it mainly
occurs during adulthood (median age in the fifth decade). Interestingly,
a very rare and distinct variant of FDC sarcoma consistently associated
with the EBV, termed inflammatory pseudotumor-like variant of FDC
sarcoma, is more prevalent in females. Approximately 10–20% of FDC
sarcoma cases have presented or concur with Castleman disease, a rare
and non-malignant lymphoproliferative disorder, typically the hyaline
vascular variant (104).
We now know also that FDC sarcomas can involve any
anatomical area besides nodal sites. FDC sarcomas generally
appear as a slow growing mass, an asymptomatic and painless
cervical lymphadenopathy (95, 104, 105). Nearly a third of FDC
sarcoma cases arise in extranodal sites: tonsils, skin, mediastinum,
gastrointestinal tract and soft tissue (104, 106, 107). Furthermore, it
seems there is an association between FDC sarcoma and the
autoimmune diseases, paraneoplastic pemphigus and myasthenia
gravis (104, 108–111).
Histopathology and cytomorphology of FDC sarcomas are
characteristic, however their identification may be difficult and
additional confirmation with immunohistochemical studies is
frequently necessary. FDC sarcomas generally present the
immunophenotype of normal FDCs, being positive for: CD21
(CR2), CD23 (Fc epsilon RII) and CD35 (CR1) (104, 112, 113).
Clusterin and podoplanin are other molecules shown to have high
sensitivity for FDC sarcomas (114–116). Clusterin shows strong
positivity with weak to no expression in other DC tumors (114).
Especially when arising from extranodal sites, FDC sarcoma
can often be misdiagnosed (106, 117). Then, differential
diagnosis is needed, including interdigitating DC sarcoma,
thymoma, spindle cell carcinoma, metastatic undifferentiated
carcinomas, malignant melanoma and gastrointestinal stromal
tumor (GIST) (104).
Clinical courses of FDC sarcomas are not consistent and
consequently, treatment schemes are variable. Complete surgical
resection seems to be the treatment of choice for both primary
and recurrent lesions, with unclear benefits from radiation and
chemical therapies (111, 118).Frontiers in Oncology | www.frontiersin.org 6FDC SARCOMA AND ITS INTERACTION
WITH LYMPHOCYTES
Being a very uncommon neoplasm, the in-depth study of FDC
sarcomas have been difficult and almost neglected. Although it has
been described an enrichment of Tfh and Treg cells in FDC
sarcomas compared to other mesenchymal tumors (119), the
interaction of malignant FDCs with other lymphocytes and other
resident cells has not yet been studied. High levels of PD-1 and its
ligands PD-L1 and PD-L2 (119) and the B/T cells mixed with the
neoplastic population (120, 121) could point to a feedback from
these lymphocytes to support the neoplastic niche and the evasion
of effector immune cells.
CONCLUDING REMARKS
As discussed in this review, although lymphomas from GC B
cells are explored in more detail and better understood, Tfh
lymphomas and FDCs sarcomas need more attention.
Tfh lymphomas diagnosis is challenging, requiring multimodality
methods including conventional cytology, immunohistochemistry,
and flow cytometry. Usually with a poor prognosis, treatments need
to be combined, frequently with unfavorable outcomes.
On the other hand, FDC sarcomas can often be misdiagnosed
and differential diagnoses are needed. With variable clinical
courses and unspecific and heterogeneous treatment at present,
surgical resection is the treatment of choice.
Greater knowledge of the normal GC microuniverse will
undoubtedly provide insights on its neoplastic side, allowing us
better diagnosis, treatment, prognosis, and monitoring, the better
to improve the quality of life of patients.
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thoughtful comments on the manuscript. RM-A is a CONACYT
fellow. RC-S and JY-P are members of the National System of
Researchers, SNI-CONACYT.January 2021 | Volume 10 | Article 587809
Munguı́a-Fuentes et al. Tfhs and FDCs MalignanciesREFERENCES
1. Berek C, Berger A, Apel M. Maturation of the immune response in germinal
centers. Cell (1991) 67(6):1121–9. doi: 10.1016/0092-8674(91)90289-B
2. Jacob J, Kelsoe G, Rajewsky K, Weiss U. Intraclonal generation of antibody
mutants in germinal centres. Nature (1991) 354(6352):389–92. doi: 10.1038/
354389a0
3. Victora GD, Nussenzweig MC. Germinal centers. Annu Rev Immunol
(2012) 30:429–57. doi: 10.1146/annurev-immunol-020711-075032
4. MacLennan IC. Germinal centers. Annu Rev Immunol (1994) 12:117–39.
doi: 10.1146/annurev.iy.12.040194.001001
5. Kuppers R, Klein U, Hansmann ML, Rajewsky K. Cellular origin of human
B-cell lymphomas. N Engl J Med (1999) 341(20):1520–9. doi: 10.1056/
NEJM199911113412007
6. Stevenson F, Sahota S, Zhu D, Ottensmeier C, Chapman C, Oscier D, et al.
Insight into the origin and clonal history of B-cell tumors as revealed by
analysis of immunoglobulin variable region genes. Immunol Rev (1998)
162:247–59. doi: 10.1111/j.1600-065X.1998.tb01446.x
7. Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and
malignancy. Nat Rev Immunol (2008) 8(1):22–33. doi: 10.1038/nri2217
8. Shulman Z, Gitlin AD, Targ S, Jankovic M, Pasqual G, Nussenzweig MC,
et al. T follicular helper cell dynamics in germinal centers. Science (2013) 341
(6146):673–7. doi: 10.1126/science.1241680
9. Victora GD, Schwickert TA, FooksmanDR, Kamphorst AO,Meyer-HermannM,
Dustin ML, et al. Germinal center dynamics revealed by multiphoton
microscopy with a photoactivatable fluorescent reporter. Cell (2010) 143
(4):592–605. doi: 10.1016/j.cell.2010.10.032
10. Vinuesa CG, Linterman MA, Yu D, MacLennan IC. Follicular Helper T
Cells. Annu Rev Immunol (2016) 34:335–68. doi: 10.1146/annurev-
immunol-041015-055605
11. Garside P, Ingulli E, Merica RR, Johnson JG, Noelle RJ, Jenkins MK.
Visualization of specific B and T lymphocyte interactions in the lymph node.
Science (1998) 281(5373):96–9. doi: 10.1126/science.281.5373.96
12. Van den Eertwegh AJ, Noelle RJ, Roy M, Shepherd DM, Aruffo A, Ledbetter
JA, et al. In vivo CD40-gp39 interactions are essential for thymus-dependent
humoral immunity. Ivivo expression of CD40 ligand, cytokines, and
antibody production delineates sites of cognate T-B cell interactions. J Exp
Med (1993) 178(5):1555–65. doi: 10.1084/jem.178.5.1555
13. MacLennan IC, Toellner KM, Cunningham AF, Serre K, Sze DM, Zuniga E,
et al. Extrafollicular antibody responses. Immunol Rev (2003) 194:8–18. doi:
10.1034/j.1600-065X.2003.00058.x
14. Coffey F, Alabyev B, Manser T. Initial clonal expansion of germinal center B
cells takes place at the perimeter of follicles. Immunity (2009) 30(4):599–609.
doi: 10.1016/j.immuni.2009.01.011
15. Camacho SA, Kosco-Vilbois MH, Berek C. The dynamic structure of the
germinal center. Immunol Today (1998) 19(11):511–4. doi: 10.1016/S0167-
5699(98)01327-9
16. Wang Y, Carter RH. CD19 regulates B cell maturation, proliferation, and
positive selection in the FDC zone of murine splenic germinal centers.
Immunity (2005) 22(6):749–61. doi: 10.1016/j.immuni.2005.04.012
17. Stratigopoulou M, van Dam TP, Guikema JEJ. Base Excision Repair in the
Immune System: Small DNA Lesions With Big Consequences. Front
Immunol (2020) 11:1084. doi: 10.3389/fimmu.2020.01084
18. Stevenson FK, Sahota SS, Ottensmeier CH, Zhu D, Forconi F, Hamblin TJ.
The occurrence and significance of V gene mutations in B cell-derived
human malignancy. Adv Cancer Res (2001) 83:81–116. doi: 10.1016/S0065-
230X(01)83004-9
19. Berglund M, Thunberg U, Amini RM, Book M, Roos G, Erlanson M, et al.
Evaluation of immunophenotype in diffuse large B-cell lymphoma and its
impact on prognosis. Mod Pathol (2005) 18(8):1113–20. doi: 10.1038/
modpathol.3800396
20. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, et al. Molecular
diagnosis of Burkitt’s lymphoma. N Engl J Med (2006) 354(23):2431–42.
doi: 10.1056/NEJMoa055759
21. Mamessier E, Broussais-Guillaumot F, Chetaille B, Bouabdallah R, Xerri L,
Jaffe ES, et al. Nature and importance of follicular lymphoma precursors.
Haematologica (2014) 99(5):802–10. doi: 10.3324/haematol.2013.085548Frontiers in Oncology | www.frontiersin.org 722. Mlynarczyk C, Fontan L, Melnick A. Germinal center-derived lymphomas:
The darkest side of humoral immunity. Immunol Rev (2019) 288(1):214–39.
doi: 10.1111/imr.12755
23. Basso K, Dalla-Favera R. Germinal centres and B cell lymphomagenesis. Nat
Rev Immunol (2015) 15(3):172–84. doi: 10.1038/nri3814
24. Heward JA, Kumar EA, Korfi K, Okosun J, Fitzgibbon J. Precision medicine
and lymphoma. Curr Opin Hematol (2018) 25(4):329–34. doi: 10.1097/
MOH.0000000000000437
25. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al.
Distinct types of diffuse large B-cell lymphoma identified by gene expression
profiling. Nature (2000) 403(6769):503–11. doi: 10.1038/35000501
26. KorfiK, Ali S, Heward JA, Fitzgibbon J. Follicular lymphoma, a B cell malignancy
addicted to epigenetic mutations. Epigenetics (2017) 12(5):370–7. doi: 10.1080/
15592294.2017.1282587
27. Krysiak K, Gomez F, White BS, Matlock M, Miller CA, Trani L, et al.
Recurrent somatic mutations affecting B-cell receptor signaling pathway
genes in follicular lymphoma. Blood (2017) 129(4):473–83. doi: 10.1182/
blood-2016-07-729954
28. Li H, Kaminski MS, Li Y, Yildiz M, Ouillette P, Jones S, et al. Mutations in linker
histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A
underlying the pathogenesis of follicular lymphoma. Blood (2014) 123(10):1487–
98. doi: 10.1182/blood-2013-05-500264
29. Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, et al. Genetic
and Functional Drivers of Diffuse Large B Cell Lymphoma. Cell (2017) 171
(2):481–94.e15. doi: 10.1016/j.cell.2017.09.027
30. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G,
et al. Confirmation of the molecular classification of diffuse large B-cell
lymphoma by immunohistochemistry using a tissue microarray. Blood
(2004) 103(1):275–82. doi: 10.1182/blood-2003-05-1545
31. Lacy SE, Barrans SL, Beer PA, Painter D, Smith AG, Roman E, et al. Targeted
sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological
Malignancy Research Network report. Blood (2020) 135(20):1759–71. doi:
10.1182/blood.2019003535
32. Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al.
Molecular subtypes of diffuse large B cell lymphoma are associated with
distinct pathogenic mechanisms and outcomes. Nat Med (2018) 24(5):679–
90. doi: 10.1038/s41591-018-0016-8
33. Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ,
et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J
Med (2018) 378(15):1396–407. doi: 10.1056/NEJMoa1801445
34. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q,
et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse
large B-cell lymphoma. Nature (2009) 459(7247):717–21. doi: 10.1038/
nature07968
35. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, et al. Chronic
active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature
(2010) 463(7277):88–92. doi: 10.1038/nature08638
36. Lenz G, Davis RE, Ngo VN, Lam L, George TC,Wright GW, et al. Oncogenic
CARD11 mutations in human diffuse large B cell lymphoma. Science (2008)
319(5870):1676–9. doi: 10.1126/science.1153629
37. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, et al.
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic
pathways. Proc Natl Acad Sci U.S.A. (2008) 105(36):13520–5. doi: 10.1073/
pnas.0804295105
38. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, et al.
Oncogenically active MYD88 mutations in human lymphoma. Nature
(2011) 470(7332):115–9. doi: 10.1038/nature09671
39. Kridel R, Sehn LH, Gascoyne RD. Pathogenesis of follicular lymphoma.
J Clin Invest (2012) 122(10):3424–31. doi: 10.1172/JCI63186
40. Montoto S, Fitzgibbon J. Transformation of indolent B-cell lymphomas.
J Clin Oncol (2011) 29(14):1827–34. doi: 10.1200/JCO.2010.32.7577
41. Choi SM, Betz BL, Perry AM. Follicular LymphomaDiagnostic Caveats andUpdates.
Arch Pathol Lab Med (2018) 142(11):1330–40. doi: 10.5858/arpa.2018-0217-RA
42. Randall C, Fedoriw Y. Pathology and diagnosis of follicular lymphoma and
related entities. Pathology (2020) 52(1):30–9. doi: 10.1016/j.pathol.2019.09.010
43. McCann KJ, Johnson PW, Stevenson FK, Ottensmeier CH. Universal N-
glycosylation sites introduced into the B-cell receptor of follicular lymphomaJanuary 2021 | Volume 10 | Article 587809
Munguı́a-Fuentes et al. Tfhs and FDCs Malignanciesby somatic mutation: a second tumorigenic event? Leukemia (2006) 20
(3):530–4. doi: 10.1038/sj.leu.2404095
44. Green MR, Gentles AJ, Nair RV, Irish JM, Kihira S, Liu CL, et al. Hierarchy
in somatic mutations arising during genomic evolution and progression of
follicular lymphoma. Blood (2013) 121(9):1604–11. doi: 10.1182/blood-
2012-09-457283
45. Li B, Chng WJ. EZH2 abnormalities in lymphoid malignancies: underlying
mechanisms and therapeutic implications. J Hematol Oncol (2019) 12
(1):118. doi: 10.1186/s13045-019-0814-6
46. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD,
et al. Frequent mutation of histone-modifying genes in non-Hodgkin
lymphoma. Nature (2011) 476(7360):298–303. doi: 10.1038/nature10351
47. Limpens J, Stad R, Vos C, de Vlaam C, de Jong D, van Ommen GJ, et al.
Lymphoma-associated translocation t(14;18) in blood B cells of normal
individuals. Blood (1995) 85(9):2528–36. doi: 10.1182/blood.V85.9.2528.
bloodjournal8592528
48. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer
(2005) 5(4):251–62. doi: 10.1038/nrc1589
49. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in
human follicular lymphoma. Science (1985) 228(4706):1440–3. doi: 10.1126/
science.3874430
50. Mulder TA, Wahlin BE, Osterborg A, Palma M. Targeting the Immune
Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical
Application. Cancers (Basel) (2019) 11(7). doi: 10.3390/cancers11070915
51. Ame-Thomas P, Tarte K. The yin and the yang of follicular lymphoma cell
niches: role of microenvironment heterogeneity and plasticity. Semin Cancer
Biol (2014) 24:23–32. doi: 10.1016/j.semcancer.2013.08.001
52. Robbiani DF, Deroubaix S, Feldhahn N, Oliveira TY, Callen E, Wang Q,
et al. Plasmodium Infection Promotes Genomic Instability and AID-
Dependent B Cell Lymphoma. Cell (2015) 162(4):727–37. doi: 10.1016/
j.cell.2015.07.019
53. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, et al. Burkitt
lymphoma pathogenesis and therapeutic targets from structural and functional
genomics. Nature (2012) 490(7418):116–20. doi: 10.1038/nature11378
54. Victora GD, Dominguez-Sola D, Holmes AB, Deroubaix S, Dalla-Favera R,
Nussenzweig MC. Identification of human germinal center light and dark
zone cells and their relationship to human B-cell lymphomas. Blood (2012)
120(11):2240–8. doi: 10.1182/blood-2012-03-415380
55. Sander S, Calado DP, Srinivasan L, Kochert K, Zhang B, Rosolowski M, et al.
Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis.
Cancer Cell (2012) 22(2):167–79. doi: 10.1016/j.ccr.2012.06.012
56. Schmitz R, Ceribelli M, Pittaluga S, Wright G, Staudt LM. Oncogenic
mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Med (2014)
4(2). doi: 10.1101/cshperspect.a014282
57. Mitchison NA. The carrier effect in the secondary response to hapten-
protein conjugates. II. Cellular cooperation. Eur J Immunol (1971) 1(1):18–
27. doi: 10.1002/eji.1830010104
58. Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A.
A 39-kDa protein on activated helper T cells binds CD40 and transduces
the signal for cognate activation of B cells. Proc Natl Acad Sci USA (1992)
89(14):6550–4. doi: 10.1073/pnas.89.14.6550
59. Ansel KM, McHeyzer-Williams LJ, Ngo VN, McHeyzer-Williams MG,
Cyster JG. In vivo-activated CD4 T cells upregulate CXC chemokine
receptor 5 and reprogram their response to lymphoid chemokines. J Exp
Med (1999) 190(8):1123–34. doi: 10.1084/jem.190.8.1123
60. Fuller KA, Kanagawa O, Nahm MH. T cells within germinal centers are
specific for the immunizing antigen. J Immunol (1993) 151(9):4505–12.
61. Gulbranson-Judge A, MacLennan I. Sequential antigen-specific growth of
T cells in the T zones and follicles in response to pigeon cytochrome c. Eur J
Immunol (1996) 26(8):1830–7. doi: 10.1002/eji.1830260825
62. Qi H, Cannons JL, Klauschen F, Schwartzberg PL, Germain RN. SAP-
controlled T-B cell interactions underlie germinal centre formation. Nature
(2008) 455(7214):764–9. doi: 10.1038/nature07345
63. Zheng B, Han S, Kelsoe G. T helper cells in murine germinal centers are
antigen-specific emigrants that downregulate Thy-1. J Exp Med (1996) 184
(3):1083–91. doi: 10.1084/jem.184.3.1083
64. Crotty S. T follicular helper cell differentiation, function, and roles in disease.
Immunity (2014) 41(4):529–42. doi: 10.1016/j.immuni.2014.10.004Frontiers in Oncology | www.frontiersin.org 865. Suan D, Nguyen A, Moran I, Bourne K, Hermes JR, Arshi M, et al.
T follicular helper cells have distinct modes of migration and molecular
signatures in naive and memory immune responses. Immunity (2015) 42
(4):704–18. doi: 10.1016/j.immuni.2015.03.002
66. Yu D, Vinuesa CG. The elusive identity of T follicular helper cells. Trends
Immunol (2010) 31(10):377–83. doi: 10.1016/j.it.2010.07.001
67. Kerfoot SM, Yaari G, Patel JR, Johnson KL, Gonzalez DG, Kleinstein SH,
et al. Germinal center B cell and T follicular helper cell development initiates
in the interfollicular zone. Immunity (2011) 34(6):947–60. doi: 10.1016/
j.immuni.2011.03.024
68. Kitano M, Moriyama S, Ando Y, Hikida M, Mori Y, Kurosaki T, et al. Bcl6
protein expression shapes pre-germinal center B cell dynamics and follicular
helper T cell heterogeneity. Immunity (2011) 34(6):961–72. doi: 10.1016/
j.immuni.2011.03.025
69. Lee SK, Rigby RJ, Zotos D, Tsai LM, Kawamoto S, Marshall JL, et al. B cell
priming for extrafollicular antibody responses requires Bcl-6 expression by T
cells. J Exp Med (2011) 208(7):1377–88. doi: 10.1084/jem.20102065
70. Lemonnier F, Gaulard P, de Leval L. New insights in the pathogenesis of T-
cell lymphomas. Curr Opin Oncol (2018) 30(5):277–84. doi: 10.1097/
CCO.0000000000000474
71. Federico M, Rudiger T, Bellei M, Nathwani BN, Luminari S, Coiffier B, et al.
Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma:
analysis of the international peripheral T-cell lymphoma project. J Clin
Oncol (2013) 31(2):240–6. doi: 10.1200/JCO.2011.37.3647
72. Lunning MA, Vose JM. Angioimmunoblastic T-cell lymphoma: the many-
faced lymphoma. Blood (2017) 129(9):1095–102. doi: 10.1182/blood-2016-
09-692541
73. de Leval L, Gisselbrecht C, Gaulard P. Advances in the understanding and
management of angioimmunoblastic T-cell lymphoma. Br J Haematol
(2010) 148(5):673–89. doi: 10.1111/j.1365-2141.2009.08003.x
74. Fujisawa M, Chiba S, Sakata-Yanagimoto M. Recent Progress in the
Understanding of Angioimmunoblastic T-cell Lymphoma. J Clin Exp
Hematop (2017) 57(3):109–19. doi: 10.3960/jslrt.17019
75. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016
revision of the World Health Organization classification of lymphoid neoplasms.
Blood (2016) 127(20):2375–90. doi: 10.1182/blood-2016-01-643569
76. Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, et al. A
targeted mutational landscape of angioimmunoblastic T-cell lymphoma.
Blood (2014) 123(9):1293–6. doi: 10.1182/blood-2013-10-531509
77. Palomero T, Couronne L, Khiabanian H, Kim MY, Ambesi-Impiombato A,
Perez-Garcia A, et al. Recurrent mutations in epigenetic regulators, RHOA
and FYN kinase in peripheral T cell lymphomas. Nat Genet (2014) 46
(2):166–70. doi: 10.1038/ng.2873
78. Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y, et al.
Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet
(2014) 46(2):171–5. doi: 10.1038/ng.2872
79. Cairns RA, Iqbal J, Lemonnier F, Kucuk C, de Leval L, Jais JP, et al. IDH2
mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood
(2012) 119(8):1901–3. doi: 10.1182/blood-2011-11-391748
80. Wang C, McKeithan TW, Gong Q, Zhang W, Bouska A, Rosenwald A, et al.
IDH2R172 mutations define a unique subgroup of patients with
angioimmunoblastic T-cell lymphoma. Blood (2015) 126(15):1741–52. doi:
10.1182/blood-2015-05-644591
81. Couronne L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in
human T-cell lymphoma. N Engl J Med (2012) 366(1):95–6. doi: 10.1056/
NEJMc1111708
82. Vallois D, Dobay MP, Morin RD, Lemonnier F, Missiaglia E, Juilland M,
et al. Activating mutations in genes related to TCR signaling in
angioimmunoblastic and other follicular helper T-cell-derived lymphomas.
Blood (2016) 128(11):1490–502. doi: 10.1182/blood-2016-02-698977
83. Yoo HY, Sung MK, Lee SH, Kim S, Lee H, Park S, et al. A recurrent
inactivating mutation in RHOA GTPase in angioimmunoblastic T cell
lymphoma. Nat Genet (2014) 46(4):371–5. doi: 10.1038/ng.2916
84. Ahearne MJ, Allchin RL, Fox CP, Wagner SD. Follicular helper T-cells:
expanding roles in T-cell lymphoma and targets for treatment. Br J
Haematol (2014) 166(3):326–35. doi: 10.1111/bjh.12941
85. Miller , Rana DN, Narine N. Angioimmunoblastic T Cell lymphoma mimics
reactive lymphoid tissue on cytomorphology: A multimodality approachJanuary 2021 | Volume 10 | Article 587809
Munguı́a-Fuentes et al. Tfhs and FDCs Malignanciesutilising cytology, immunocytochemistry and flow cytometry to resolve this
diagnostic dilemma. Cytopathology (2017) 28(3):239–41. doi: 10.1111/
cyt.12422
86. Attygalle AD. Nodal T-cell lymphomas with a T-follicular helper cell
phenotype. Diagn Histopathol (2018) 24(7):227–36. doi: 10.1016/
j.mpdhp.2018.05.006
87. Dobay MP, Lemonnier F, Missiaglia E, Bastard C, Vallois D, Jais JP, et al.
Integrative clinicopathological and molecular analyses of angioimmunoblastic T-
cell lymphoma and other nodal lymphomas of follicular helper T-cell origin.
Haematologica (2017) 102(4):e148–51. doi: 10.3324/haematol.2016.158428
88. Streubel B, Vinatzer U, Willheim M, Raderer M, Chott A. Novel t(5;9)(q33;
q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia
(2006) 20(2):313–8. doi: 10.1038/sj.leu.2404045
89. Suzuki T, Miyoshi H, Yanagida E, Kawamoto K, Yamada K, Takeuchi M, et al.
Clinicopathological differences of nodal ptcl with tfh phenotype from aitl and
ptcl, nos, and detection of prognostic marker of nodal ptcl with tfh phenotype.
15th International Conference onMalignant Lymphoma. Lugano, Switzerland:
Hematological Oncology (2019). p. 276–7. doi: 10.1002/hon.87_2630
90. Crotty S. T Follicular Helper Cell Biology: A Decade of Discovery and
Diseases. Immunity (2019) 50(5):1132–48. doi: 10.1016/j.immuni.2019.04.011
91. Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T, Kucuk C,
et al. Molecular signatures to improve diagnosis in peripheral T-cell
lymphoma and prognostication in angioimmunoblastic T-cell lymphoma.
Blood (2010) 115(5):1026–36. doi: 10.1182/blood-2009-06-227579
92. Bruneau J, Canioni D, Renand A, Marafioti T, Paterson JC, Martin-Garcia N,
et al. Regulatory T-cell depletion in angioimmunoblastic T-cell lymphoma.
Am J Pathol (2010) 177(2):570–4. doi: 10.2353/ajpath.2010.100150
93. Aguzzi A, Kranich J, Krautler NJ. Follicular dendritic cells: origin,
phenotype, and function in health and disease. Trends Immunol (2014) 35
(3):105–13. doi: 10.1016/j.it.2013.11.001
94. Chen LL, Adams JC, Steinman RM. Anatomy of germinal centers in mouse
spleen, with special reference to “follicular dendritic cells”. J Cell Biol (1978)
77(1):148–64. doi: 10.1083/jcb.77.1.148
95. Facchetti F, Lorenzi L. Follicular dendritic cells and related sarcoma. Semin
Diagn Pathol (2016) 33(5):262–76. doi: 10.1053/j.semdp.2016.05.002
96. Szakal AK, Gieringer RL, Kosco MH, Tew JG. Isolated follicular dendritic
cells: cytochemical antigen localization, Nomarski, SEM, and TEM
morphology. J Immunol (1985) 134(3):1349–59.
97. Aguzzi A, Krautler NJ. Characterizing follicular dendritic cells: A progress
report. Eur J Immunol (2010) 40(8):2134–8. doi: 10.1002/eji.201040765
98. Allen CD, Cyster JG. Follicular dendritic cell networks of primary follicles
and germinal centers: phenotype and function. Semin Immunol (2008) 20
(1):14–25. doi: 10.1016/j.smim.2007.12.001
99. Mackay F, Majeau GR, Lawton P, Hochman PS, Browning JL. Lymphotoxin
but not tumor necrosis factor functions to maintain splenic architecture and
humoral responsiveness in adult mice. Eur J Immunol (1997) 27(8):2033–42.
doi: 10.1002/eji.1830270830
100. Ware CF. Network communications: lymphotoxins, LIGHT, and TNF. Annu
Rev Immunol (2005) 787–819. doi: 10.1146/annurev.immunol.23.021704.
115719
101. Carroll MC, Isenman DE. Regulation of humoral immunity by complement.
Immunity (2012) 37(2):199–207. doi: 10.1016/j.immuni.2012.08.002
102. Jarjour M, Jorquera A, Mondor I, Wienert S, Narang P, Coles MC, et al. Fate
mapping reveals origin and dynamics of lymph node follicular dendritic
cells. J Exp Med (2014) 211(6):1109–22. doi: 10.1084/jem.20132409
103. Krautler NJ, Kana V, Kranich J, Tian Y, Perera D, Lemm D, et al. Follicular
dendritic cells emerge from ubiquitous perivascular precursors. Cell (2012)
150(1):194–206. doi: 10.1016/j.cell.2012.05.032
104. Wu A, Pullarkat S. Follicular Dendritic Cell Sarcoma. Arch Pathol Lab Med
(2016) 140(2):186–90. doi: 10.5858/arpa.2014-0374-RS
105. Choe JY, Go H, Jeon YK, Yun JY, Kim YA, Kim HJ, et al. Inflammatory
pseudotumor-like follicular dendritic cell sarcoma of the spleen: a report of
six cases with increased IgG4-positive plasma cells. Pathol Int (2013) 63
(5):245–51. doi: 10.1111/pin.12057
106. Duan GJ, Wu F, Zhu J, Guo DY, Zhang R, Shen LL, et al. Extranodal
follicular dendritic cell sarcoma of the pharyngeal region: a potential
diagnostic pitfall, with literature review. Am J Clin Pathol (2010) 133
(1):49–58. doi: 10.1309/AJCP7U8YISBUAVNWFrontiers in Oncology | www.frontiersin.org 9107. Perez-Ordonez B, Rosai J. Follicular dendritic cell tumor: review of the entity.
Semin Diagn Pathol (1998) 15(2):144–54.
108. Hsu C, Vega F, Grimes LM, Hunt KK. Follicular dendritic cell sarcoma and
associated myasthenia gravis: true, true, related? J Clin Oncol (2011) 29(13):
e369–71. doi: 10.1200/JCO.2010.32.7932
109. Lee IJ, Kim SC, Kim HS, Bang D, Yang WI, Jung WH, et al. Paraneoplastic
pemphigus associated with follicular dendritic cell sarcoma arising from
Castleman’s tumor. J Am Acad Dermatol (1999) 40(2 Pt 2):294–7. doi:
10.1016/S0190-9622(99)70468-8
110. Meijs M, Mekkes J, van Noesel C, Nijhuis E, Leeksma O, Jonkman M, et al.
Paraneoplastic pemphigus associated with follicular dendritic cell sarcoma
without Castleman’s disease; treatment with rituximab. Int J Dermatol (2008)
47(6):632–4. doi: 10.1111/j.1365-4632.2008.03444.x
111. Saygin C, Uzunaslan D, Ozguroglu M, Senocak M, Tuzuner N. Dendritic cell
sarcoma: a pooled analysis including 462 cases with presentation of our case
series. Crit Rev Oncol Hematol (2013) 88(2):253–71. doi: 10.1016/
j.critrevonc.2013.05.006
112. Chan JK, Fletcher CD, Nayler SJ, Cooper K. Follicular dendritic cell sarcoma.
Clinicopathologic analysis of 17 cases suggesting a malignant potential
higher than currently recognized. Cancer (1997) 79(2):294–313. doi:
10.1002/(SICI)1097-0142(19970115)79:2<294::AID-CNCR13>3.0.CO;2-W
113. Soriano AO, ThompsonMA, Admirand JH, Fayad LE, Rodriguez AM, Romaguera
JE, et al. Follicular dendritic cell sarcoma: a report of 14 cases and a review of the
literature. Am J Hematol (2007) 82(8):725–8. doi: 10.1002/ajh.20852
114. Grogg KL, Lae ME, Kurtin PJ, MaconWR. Clusterin expression distinguishes
follicular dendritic cell tumors from other dendritic cell neoplasms: report of
a novel follicular dendritic cell marker and clinicopathologic data on 12
additional follicular dendritic cell tumors and 6 additional interdigitating
dendritic cell tumors. Am J Surg Pathol (2004) 28(8):988–98. doi: 10.1097/
01.pas.0000112536.76973.7f
115. Grogg KL, MaconWR, Kurtin PJ. A survey of clusterin and fascin expression
in sarcomas and spindle cell neoplasms: strong clusterin immunostaining is
highly specific for follicular dendritic cell tumor. Mod Pathol (2005) 18
(2):260–6. doi: 10.1038/modpathol.3800294
116. Yu H, Gibson JA, Pinkus GS, Hornick JL. Podoplanin (D2-40) is a novel
marker for follicular dendritic cell tumors. Am J Clin Pathol (2007) 128
(5):776–82. doi: 10.1309/7P8U659JBJCV6EEU
117. Shia J, Chen W, Tang LH, Carlson DL, Qin J, Guillem JG, et al. Extranodal
follicular dendritic cell sarcoma: clinical, pathologic, and histogenetic
characteristics of an underrecognized disease entity. Virchows Arch (2006)
449(2):148–58. doi: 10.1007/s00428-006-0231-4
118. Perez-Ordonez B, Erlandson RA, Rosai J. Follicular dendritic cell tumor:
report of 13 additional cases of a distinctive entity. Am J Surg Pathol (1996)
20(8):944–55. doi: 10.1097/00000478-199608000-00003
119. Laginestra MA, Tripodo C, Agostinelli C, Motta G, Hartmann S, Doring C,
et al. Distinctive Histogenesis and Immunological Microenvironment Based
on Transcriptional Profiles of Follicular Dendritic Cell Sarcomas.Mol Cancer
Res (2017) 15(5):541–52. doi: 10.1158/1541-7786.MCR-16-0301
120. Huang W, Qiu T, Zeng L, Zheng B, Ying J, Feng X. High frequency of clonal
IG and T-cell receptor gene rearrangements in histiocytic and dendritic cell
neoplasms. Oncotarget (2016) 7(48):78355–62. doi: 10.18632/
oncotarget.13058
121. Pileri SA, Grogan TM, Harris NL, Banks P, Campo E, Chan JK, et al. Tumours of
histiocytes and accessory dendritic cells: an immunohistochemical approach to
classification from the International Lymphoma Study Group based on 61 cases.
Histopathology (2002) 41(1):1–29. doi: 10.1046/j.1365-2559.2002.01418.x
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
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